How longer-lasting therapies cut injection burden, boost adherence, and protect vision in AMD, DME, and RVO with ...

A novel intravitreal axitinib hydrogel demonstrated durable disease control in patients with treatment-naive neovascular age-related macular degeneration (AMD), with superior maintenance of visual ...

Quantified preferences favored higher lesion growth rate reduction (10%→50% at 18 months) as the primary driver across all ...

New trial data show aflibercept 8 mg and faricimab extend dosing to 16–20 weeks in AMD, DME, RVO while maintaining safety.

CHICAGO -- Retinal injections for eye disease had a significant association with increased complications rates after cataract surgery, according to a large retrospective cohort study. Seven different ...

Patients with neovascular age‑related macular degeneration (AMD) whose retinal fluid cleared within 12 weeks of starting faricimab were more likely to have longer intervals between injections later in ...

The market for treatments for macular degeneration, cited as the leading cause of blindness in the elderly, is growing rapidly. Macular degeneration is a condition where abnormal blood vessels grow ...

Clearside Biomedical, Inc. has announced that its suprachoroidal injection delivery platform will be prominently featured at the Clinical Trials at the Summit (CTS) Meeting on June 21, 2025, in Las ...

Inflammatory retinal diseases are different from most retinal disorders because they are caused by infections or an abnormal ...